Natural Capsules Limited has informed the Exchange regarding a press release dated August 04, 2025, titled "NATURAL CAPSULES LIMITED REPORTS Q1FY26 RESULTS".
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natural Capsules Limited reported its Q1FY26 results with revenue of ₹45.20 Cr, down 52% quarter-on-quarter but up 15.36% year-on-year. The company swung to a loss with a PAT of ₹(5.58) Cr and EPS of ₹(5.40), while EBITDA collapsed to just ₹0.32 Cr with margins at a razor-thin 0.71% (down 904 basis points QoQ). Management attributed the weak performance to the first full quarter of expense impact from the newly capitalized API facility at subsidiary Natural Biogenex. Management remains optimistic, citing moderation in gelatin prices, robust demand for Indian HPMC capsules due to US duties on Chinese products, and plans to add two more capsule production lines.
This is a clearly disappointing quarter with a deep loss and collapsing margins, which is likely to weigh negatively on the stock in the near term. However, the strategic positives (HPMC export opportunity, API ramp-up, capacity expansion) and management's confidence in a recovery from Q2 onwards could provide some long-term support for investors who believe in the turnaround story.